Loading
StemRIM Inc.: what insiders have been doing
Only a handful of insider records exist for StemRIM Inc., the last one from 20 August 2026, too few to describe a trend. This summary is built from EDINET (Japan FSA) disclosures alone and does not predict where the share price will go.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended July 2024 · cache
JP¥172
Analyst consensus
1 analystsJP¥700Target JP¥700(+307%)JP¥700
Income statement
EBITDA-JP¥2B
Net income-JP¥2B0.0% margin
Valuation
P/Book1.9x
Beta0.96
Balance sheet & cash
Market capJP¥10.8B
Free Cash Flow-JP¥1.9B
Profitability & ownership
ROE-28.4%
ROA-18.6%
% insiders47.9%
% institutions0.2%
Last declaration on 20 August 2026
Declarations4 total
35.1% of flowShareXTKSEDINET:S100YXRX
64.9% of flowShareXTKSEDINET:S100QTQZ
50.0% of flowShareXTKSEDINET:S100QRVJ
50.0% of flowShareXTKSEDINET:S100QN9I
4 of 4 declarations
About StemRIM Inc.
株式会社ステムリム is a Japanese company operating in the healthcare and pharmaceutical sector. It is listed on the XTKS market.